Financials in USD. Standardized financial statements.
A compact view of how Relief Therapeutics Holding AG turns revenue into operating income and net income.
| Metric | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 | FY 2015 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue? | $8.42M | $6.03M | $6.08M | $3.32M | $0 | $0 | $567,000 | $0 | $15,000 | $256,117 |
| Revenue Growth? | +39.5% | -0.8% | +83.1% | 0.0% | 0.0% | -100.0% | 0.0% | -100.0% | -94.1% | 0.0% |
| Cost of Revenue? | $2.58M | $1.92M | $18.11M | $11.91M | $0 | $1,000 | $55,000 | $3,000 | $211,000 | $2.08M |
| Gross Profit? | $5.84M | $4.11M | $4.83M | -$8.59M | $0 | -$1,000 | $512,000 | -$3,000 | -$196,000 | -$1.83M |
| Gross Margin? | +69.4% | +68.2% | +79.4% | -258.5% | 0.0% | 0.0% | +90.3% | 0.0% | -1306.7% | -713.0% |
| Operating Expenses? | $24.73M | $114.94M | $56.87M | $26.62M | $19.30M | $946,000 | $788,000 | $1.24M | $16.29M | $1.99M |
| Operating Income? | -$18.89M | -$110.83M | -$52.04M | -$34.31M | -$19.30M | -$947,000 | -$500,000 | -$1.25M | -$16.49M | -$3.82M |
| EBITDA? | -$16.58M | -$108.04M | -$49.02M | -$32.69M | -$6.09M | -$946,000 | -$259,000 | -$1.73M | -$16.48M | -$81,000 |
| Income Before Tax | -$19.36M | -$111.68M | -$54.32M | -$35.52M | -$6.26M | -$12.16M | -$416,000 | -$1.90M | -$16.81M | -$81,000 |
| Income Tax Expense | -$2.24M | -$13.50M | -$3.53M | -$820,000 | $1.57M | -$4.70M | $20,000 | $986,000 | $20,000 | -$87,533 |
| Net Income? | -$17.12M | -$98.18M | -$50.79M | -$34.70M | -$7.83M | -$7.46M | -$436,000 | -$2.89M | -$16.83M | -$9.15M |
| EPS? | $-1.36 | $-8.35 | $-4.80 | $-3.86 | $-1.30 | $-1.42 | $-0.09 | $-0.58 | $-5.32 | $-0.06 |
| Diluted EPS? | $-1.36 | $-8.35 | $-4.80 | $-3.86 | $-1.30 | $-1.42 | $-0.09 | $-0.58 | $-5.32 | $-0.06 |
Revenue, profitability, margins, EPS, and share-count trends over time.
Top-line demand and scale over time
Profit left after direct production costs
Core business profitability before financing and tax
Bottom-line profit after all expenses
Profit allocated to each diluted share
Share count trend that affects EPS quality
Gross, operating, and net margin quality